While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, outlines how the company is ...

Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...

The supplemental New Drug Application is supported by Phase III data, which showed Caplyta significantly prolonged time to ...

The National Alliance on Mental Illness (NAMI) issued a response to the bill, stating that the cuts to Medicare and Medicaid ...

Traditionally, COVID vaccines have been delivered via injections. According to the Cincinnati Children’s Hospital Medical ...

The Phase II THULITE trial will analyze the safety and efficacy of BI 1815368, an investigational oral therapy designed to ...

Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

Lunit and Microsoft are working together to push for the use of AI in cancer diagnosis. Lunit and Microsoft are working ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, shares how the company is ...

What’s impacting medical affairs today is the update to drug approvals: there’s more visibility, more scrutiny, and more ...